Zevra Therapeutics (ZVRA) Cash & Current Investments (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Cash & Current Investments data on file, last reported at $200.6 million in Q1 2026.

• Quarterly Cash & Current Investments rose 220.31% year-over-year to $200.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.6 million (up 220.31% YoY) and the FY2025 annual result came in at $191.0 million, up 174.85% from the prior year.
• Cash & Current Investments rose to $200.6 million in Q1 2026, from $191.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $202.6 million in Q2 2025 to a low of $479000.0 in Q2 2023.
• A 5-year average of $92.6 million and a median of $68.6 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 99.38% — and 2024, when it surged 10183.51%.
• Tracing ZVRA's Cash & Current Investments over 5 years: stood at $65.9 million in 2022, then rose by 2.71% to $67.7 million in 2023, then increased by 2.6% to $69.5 million in 2024, then surged by 174.85% to $191.0 million in 2025, then advanced by 5.03% to $200.6 million in 2026.
• The last three Cash & Current Investments figures came in at $200.6 million (Q1 2026), $191.0 million (Q4 2025), and $199.5 million (Q3 2025), per Business Quant data.